Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ORTC Ortec International -- Ignore unavailable to you. Want to Upgrade?

To: Lane Hall-Witt who wrote (256)	2/24/2000 11:36:00 AM
From: Lane Hall-Witt	Read Replies (1) \| Respond to of 272

One thing I should clarify from the previous post is that ORTC will have exclusive commercial access to the EB, EM, TEN, and SJS markets for at least seven years, under the Humanitarian Device Exemption (HDE) that the company has already received from the FDA. That means ORTC will be the sole vendor within this $22 million/year U.S. market. HDEs are granted under the Orphan Drug Act and are designed to encourage the development of treatments for conditions with small patient populations (4,000 patients per year, or less).